Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2233-2235

  Mencoboni, Manlio ^a   Tredici, S ^a   Rebella, L ^a   Bergaglio, M ^a   Galbusera, V ^a   Manzara, A ^a   Claudiani, F ^a   Malcangi, B ^a   Varaldo, M ^a  

^a VILLA SCASSI HOSPITAL   (Italy)

Author keywords

Hormone refractory prostate cancer; Somatostatin analogs

Indexed keywords

DOCETAXEL; HORMONE; INDIUM 111; NAVELBINE; OCTREOTIDE; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SCINTIGRAPHY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TAXOIDS; VINBLASTINE;

EID: 33745517585     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Aprikian AG, Cordon-Cardo C, Fair WR and Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71(12): 3952-3965, 1993.
2. Mosca A, Dogliotti L, Berruti A, Lamberts SW and Hofland LJ: Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: prostate cancer. Dig Liver Dis 36 Suppl 1: S60-67, 2004.
3. Hirano D, Okada Y, Minei S, Takimoto Y and Nemoto N: Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45(5): 586-592, 2004.
4. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A and Dogliotti L: Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12(1): 109-117, 2005.
5. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, Tarabuzzi R, Poggio M, Torta M, Fontana D and Angeli A: Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 12 Suppl 2: S153-157, 2001.
6. Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, Fontana D and Angeli A: Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate 47(3): 205-211, 2001.
7. Chuang CK, Wu TL, Tsao KC and Liao SK: Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc 102(7): 480-485, 2003.
8. Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J and Karamanolakis D: Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin Investig Drugs 11(2): 283-293, 2002.
9. Cabrespine A, Guy L, Chollet P, Debiton E and Bay JO: Molecular mechanisms involved in hormone resistance of prostate cancer. Bull Cancer 91(10): 747-757, 2004.
10. Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR and Chen LT: Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review. Oncology 67(3-4): 320-326, 2004.
11. Della Porta M, Danova M, Rigolin GM, Brugnatelli S, Rovati B, Tronconi C, Fraulini C, Russo Rossi A, Riccardi A and Castoldi G: Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 68(2-3): 276-284, 2005.
12. Nilsson S, Reubi JC, Kalkner KM, Laissue JA, Horisberger U, Olerud C and Westlin JE: Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res 55(23 Suppl): 5805s-5810s, 1995.
13. Vashchenko N and Abrahamsson PA: Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47(2): 147-155, 2005.